个人简历
华西医院肿瘤中心副主 任 医师 。 1997 年毕业于华西医科大学获临床医学硕士学位，2003 年获得四川大学肿瘤学专业博士学位， 2005 年于中山大学肿瘤防治中心完 成 博士后深造。主持了 5 项国家级医学科研课题及 4 项省部级课题的研究工作，近年来发表文章 40 多篇，包括 SCI 论著 10 余篇。参加 5 部肿瘤学专著的编写。主要从事以肿瘤分子靶向治疗，生物免疫治疗为主的肿瘤基础研究及内科治疗工作。
研究领域
肿瘤分子靶向治疗的基础研究及临床应用； 抗肿瘤血管生成治疗的基础与临床研究；抗肿瘤药物耐药机制；肿瘤免疫调节
近期论文
Liu Ji-Yan , Wei YQ, Yang L, et al. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood . 2003;102(5):1815-23. Liu Ji-Yan, Zhang XS, Ding Y, et al. The changes of CD4+CD25+/CD4+ proportion in spleen of tumor-bearing BALB/c mice. J Transl Med . 2005;3:5 Liu Ji-Yan, Wu Y, Zhang XS, et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother. 2007;56:1597-1604. Hou JM, Liu Ji-Yan , Yang Li, et al. Combination of low-dose gemcitabine and recombinant xenogeneic vascular endothelial growth factor receptor-2 as a vaccine induces synergistic anti-tumor activities. Oncology . 2005;69(1):81-87. Zhang Wei, Liu Jiyan , Wu Yang, Xiao Fei, Wang Yongsheng, Wang Rui, Yang Hanshuo, Wang Guoqing, Yang Jinliang, Deng Hongxin, Li Jiong, Wen Yanjun, Wei Yuquan. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice. Biochem Biophys Res Commun. 2008;376(1):10-4 Wu Y, Yang L, Hu B, Liu JY , et al. Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine. Anticancer Drugs. 2005 Jun;16(5):551-7. Jiang Y, Wei YQ, Luo F, Zou LQ, Liu JY , et al. Gemcitabine and cisplatin in advanced nasopharyngeal carcinoma: a pilot study. Cancer Invest. 2005;23(2):123-8. Peng XC, Yang L, Yang LP, Mao YQ, Yang HS, Liu JY , Zhang DM, Chen LJ, Wei YQ. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34--> Ala mutant. J Exp Clin Cancer Res . 2008 Sep 25;27:46. Bai RZ, Wu Y, Liu Q, Xie K, Wei YQ, Wang YS, Liu K, Luo Y, Su JM, Hu B, Liu JY , Li Q, Niu T, Zhao ZW, Yang L. Suppression of lung cancer in murine model: treated by combination of recombinant human endostsatin adenovirus with low-dose cisplatin. J Exp Clin Cancer Res . 2009 Mar 5;28:31
